Sarepta Therapeutics Management
Management criteria checks 4/4
Sarepta Therapeutics' CEO is Doug Ingram, appointed in Jun 2017, has a tenure of 7.5 years. total yearly compensation is $1.66M, comprised of 48.1% salary and 51.9% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $46.43M. The average tenure of the management team and the board of directors is 4 years and 8.5 years respectively.
Key information
Doug Ingram
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 48.1% |
| CEO tenure | 7.5yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$122m |
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
| Sep 30 2019 | n/a | n/a | -US$620m |
| Jun 30 2019 | n/a | n/a | -US$570m |
| Mar 31 2019 | n/a | n/a | -US$403m |
| Dec 31 2018 | US$1m | US$650k | -US$362m |
| Sep 30 2018 | n/a | n/a | -US$245m |
| Jun 30 2018 | n/a | n/a | -US$216m |
| Mar 31 2018 | n/a | n/a | -US$170m |
| Dec 31 2017 | US$57m | US$338k | -US$51m |
Compensation vs Market: Doug's total compensation ($USD1.66M) is below average for companies of similar size in the US market ($USD12.85M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
CEO
Doug Ingram (61 yo)
7.5yrs
Tenure
US$1,661,338
Compensation
Mr. Douglas S. Ingram, also known as Doug, is Director of Arrowhead Pharmaceuticals, Inc. from November 2024. Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and Pre...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.5yrs | US$1.66m | 0.41% $ 46.4m | |
| Executive VP & CFO | 4yrs | US$3.71m | 0.036% $ 4.0m | |
| Executive VP & Chief Technical Operations Officer | 2yrs | US$3.52m | 0.018% $ 2.1m | |
| Executive VP | 4yrs | US$3.72m | 0.071% $ 8.0m | |
| Executive VP | 4yrs | US$3.58m | 0.018% $ 2.0m | |
| Executive Director of Investor Relations and Corporate Communications | no data | no data | no data | |
| Executive VP & Chief People Officer | 3.2yrs | no data | no data | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 5.3yrs | no data | no data | |
| Executive VP & Chief Customer Officer | 4yrs | no data | 0.023% $ 2.6m | |
| Senior VP | 1.9yrs | no data | no data | |
| Controller & VP | 7.8yrs | US$911.89k | no data | |
| Senior Manager of Investor Relations | no data | no data | no data |
4.0yrs
Average Tenure
50yo
Average Age
Experienced Management: SRPT's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.5yrs | US$1.66m | 0.41% $ 46.4m | |
| Independent Chairwoman | 15.8yrs | US$594.99k | 0.21% $ 23.7m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 14.5yrs | US$546.99k | 0.022% $ 2.5m | |
| Independent Director | 9.5yrs | US$563.65k | 3.33% $ 378.3m | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | no data | no data | |
| Independent Non-Employee Director | 9.5yrs | US$553.34k | 0.017% $ 1.9m | |
| Member of Strategic & Scientific Advisory Board | 7.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 7.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data |
8.5yrs
Average Tenure
71yo
Average Age
Experienced Board: SRPT's board of directors are considered experienced (8.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sarepta Therapeutics, Inc. is covered by 54 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Zhiqiang Shu | Berenberg |